-
Je něco špatně v tomto záznamu ?
Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses
L. Eyer, R. Nencka, E. de Clercq, K. Seley-Radtke, D. Růžek,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
Grantová podpora
NV16-34238A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 1999 do Před 1 rokem
PubMed Central
od 2015 do 2023
Europe PubMed Central
od 2015
ProQuest Central
od 2017-01-01
Health & Medicine (ProQuest)
od 2017-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1990 do 2023
PubMed
29534608
DOI
10.1177/2040206618761299
Knihovny.cz E-zdroje
- MeSH
- antivirové látky chemie farmakologie MeSH
- Culicidae virologie MeSH
- Flavivirus účinky léků MeSH
- infekce viry z rodu Flavivirus farmakoterapie virologie MeSH
- mikrobiální testy citlivosti MeSH
- molekulární struktura MeSH
- nukleosidy chemie farmakologie MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Nucleoside analogs represent the largest class of small molecule-based antivirals, which currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis B or C viruses, and herpes viruses. High antiviral potency and favorable pharmacokinetics parameters make some nucleoside analogs suitable also for the treatment of acute infections caused by other medically important RNA and DNA viruses. This review summarizes available information on antiviral research of nucleoside analogs against arthropod-borne members of the genus Flavivirus within the family Flaviviridae, being primarily focused on description of nucleoside inhibitors of flaviviral RNA-dependent RNA polymerase, methyltransferase, and helicase/NTPase. Inhibitors of intracellular nucleoside synthesis and newly discovered nucleoside derivatives with high antiflavivirus potency, whose modes of action are currently not completely understood, have drawn attention. Moreover, this review highlights important challenges and complications in nucleoside analog development and suggests possible strategies to overcome these limitations.
Department of Chemistry and Biochemistry University of Maryland Baltimore USA
Rega Institute for Medical Research KU Leuven Leuven Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028526
- 003
- CZ-PrNML
- 005
- 20230808135031.0
- 007
- ta
- 008
- 190813s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/2040206618761299 $2 doi
- 035 __
- $a (PubMed)29534608
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Eyer, Luděk $u 1 Department of Virology, Veterinary Research Institute, Brno, Czech Republic. 2 Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, České Budějovice, Czech Republic. $7 xx0098551
- 245 10
- $a Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses / $c L. Eyer, R. Nencka, E. de Clercq, K. Seley-Radtke, D. Růžek,
- 520 9_
- $a Nucleoside analogs represent the largest class of small molecule-based antivirals, which currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis B or C viruses, and herpes viruses. High antiviral potency and favorable pharmacokinetics parameters make some nucleoside analogs suitable also for the treatment of acute infections caused by other medically important RNA and DNA viruses. This review summarizes available information on antiviral research of nucleoside analogs against arthropod-borne members of the genus Flavivirus within the family Flaviviridae, being primarily focused on description of nucleoside inhibitors of flaviviral RNA-dependent RNA polymerase, methyltransferase, and helicase/NTPase. Inhibitors of intracellular nucleoside synthesis and newly discovered nucleoside derivatives with high antiflavivirus potency, whose modes of action are currently not completely understood, have drawn attention. Moreover, this review highlights important challenges and complications in nucleoside analog development and suggests possible strategies to overcome these limitations.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antivirové látky $x chemie $x farmakologie $7 D000998
- 650 _2
- $a Culicidae $x virologie $7 D009033
- 650 _2
- $a Flavivirus $x účinky léků $7 D005416
- 650 _2
- $a infekce viry z rodu Flavivirus $x farmakoterapie $x virologie $7 D018177
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a nukleosidy $x chemie $x farmakologie $7 D009705
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Nencka, Radim $u 3 Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a de Clercq, Erik $u 4 Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Seley-Radtke, Katherine $u 5 Department of Chemistry and Biochemistry, University of Maryland, Baltimore, USA.
- 700 1_
- $a Růžek, Daniel, $u 1 Department of Virology, Veterinary Research Institute, Brno, Czech Republic. 2 Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, České Budějovice, Czech Republic. $d 1981- $7 stk2008441707
- 773 0_
- $w MED00193671 $t Antiviral chemistry & chemotherapy $x 2040-2066 $g Roč. 26, č. - (2018), s. 2040206618761299
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29534608 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20230808135028 $b ABA008
- 999 __
- $a ok $b bmc $g 1433675 $s 1066986
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 26 $c - $d 2040206618761299 $e - $i 2040-2066 $m Antiviral chemistry & chemotherapy $n Antivir Chem Chemother $x MED00193671
- GRA __
- $a NV16-34238A $p MZ0
- LZP __
- $a Pubmed-20190813